Teneligliptin + Metformin HCL
The combination of Teneligliptin and Metformin HCL is an effective treatment for managing type 2 diabetes mellitus. Teneligliptin is a DPP-4 inhibitor that enhances the secretion of insulin and suppresses glucagon levels in response to meals. Metformin is a first-line antidiabetic agent that works by decreasing hepatic glucose production and improving insulin sensitivity. Together, they provide synergistic glycemic control.
- Recommended Usage
Indications:
- Management of type 2 diabetes mellitus in adults.
- As an adjunct to diet and exercise to achieve better glycemic control.
- Can be used as monotherapy or in combination with other antidiabetic agents.
Dosage and Administration:
- Administered orally, typically twice daily with meals to minimize gastrointestinal side effects.
- Dosage depends on the formulation and patient needs:
- Common doses: Teneligliptin 20mg + Metformin 500mg/850mg/1000mg.
- Maximum daily dose: Teneligliptin 20mg and Metformin 2000mg.
- Dosage adjustments may be required based on renal function and glycemic control.
Precautions:
- Contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to any component.
- Use with caution in patients with hepatic impairment or cardiovascular disease.
- Regular monitoring of renal function and blood glucose levels is recommended.
- Discontinue immediately if lactic acidosis is suspected.
Key Benefits:
- Dual Mechanism: Provides comprehensive glycemic control by targeting both insulin secretion and glucose production.
- Enhanced Postprandial Control: Effectively lowers post-meal blood glucose levels.
- Well-Tolerated: Minimal risk of hypoglycemia when used as directed.
- Convenience: Single-tablet combination improves patient adherence.
